The cases are originating from endemic areas in the Amazon basin as well as new areas in South America and the Caribbean, according to an Aug. 16 news release from the agency.
There have been more than 8,000 Oropouche virus cases reported in 2024 from Brazil, Bolivia, Peru, Colombia and Cuba.
Though travel-associated cases have been identified in the U.S. and Europe from individuals who traveled to Cuba and Brazil, “no evidence of local transmission currently exists within the United States or its territories,” the release said.
Here are eight things physicians should know about Oropouche virus, according to the release:
- Pregnant people are recommended to reconsider non-essential travel to areas with reported cases of Oropouche virus.
- Approximately 60% of Oropouche virus infected individuals will become symptomatic.
- Oropouche virus has a typical incubation period of three to 10 days.
- Symptoms of Oropouche virus include fever, chills, headache, muscle aches and joint stiffness.
- An estimated fewer than 5% of patients will develop symptoms beyond the typical mild illness. More serious symptoms can include hemorrhagic manifestation or neuroinvasive disease.
- Physicians should contact their local health department to facilitate testing if necessary.
- There are no vaccines or antiviral treatments for Oropouche virus.
- Physicians who suspect a patient may have Oropouche virus disease should rule out dengue virus infection.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
